blue-overlay
blue-overlay

Press Releases

April 10, 2017

FORMA THERAPEUTICS DELIVERS TWO KEY OBJECTIVES IN COLLABORATION WITH CELGENE CORPORATION TO ADVANCE PROTEIN HOMEOSTASIS MEDICINES TO BENEFIT PATIENTS

WATERTOWN, Mass. – April 10, 2017 – FORMA Therapeutics announced today that it has successfully completed two additional objectives under its strategic collaboration agreement with…

March 13, 2017

FORMA THERAPEUTICS ANNOUNCES ACHIEVEMENT OF FIRST CLINICAL DEVELOPMENT MILESTONE IN PARTNERSHIP WITH BOEHRINGER INGELHEIM

WATERTOWN, Mass. – March 13, 2017 – FORMA Therapeutics, a clinical-stage and fully integrated discovery and development company, today announced the achievement of a clinical…

February 21, 2017

FORMA THERAPEUTICS AWARDED GRANT FROM MICHAEL J. FOX FOUNDATION FOR PARKINSON’S RESEARCH

FORMA Therapeutics receives grant from MJFF and expands translational research into neurodegenerative diseases through alliance with University of Liverpool and Medical Research Council. WATERTOWN, Mass….

October 11, 2016

FORMA THERAPEUTICS APPOINTS JIM WINKLER, PH.D., VICE PRESIDENT, DISCOVERY AND TRANSLATIONAL BIOLOGY

WATERTOWN, Mass. — October 11, 2016 — FORMA Therapeutics, a clinical-stage and fully integrated research and development company, today announced the appointment of Jim Winkler,…

August 31, 2016

FORMA THERAPEUTICS ACHIEVES CLINICAL CANDIDATE LICENSING MILESTONE FOR NASH COMPOUND IN STRATEGIC ALLIANCE WITH CELGENE CORPORATION

FORMA Therapeutics delivers second Phase I-ready compound under Celgene alliance WATERTOWN, Mass. – August 31, 2016 – FORMA Therapeutics (FORMA) announced today that they have…

News & Events

June 2, 2017 / Managing Intellectual Property

Karoline Shair of FORMA Therapeutics Recognized as a 2017 Corporate IP Star

September 21, 2016 / Discovery on Target

Stephanos Ioannidis presents at 14th annual Discovery on Target conference, "Discovery of Novel Protein Homeostasis Inhibitors Utilizing FORMA’s Drug Discovery Engine"

September 19, 2016 / Event: Discovery on Target

THERAPEUTIC POTENTIAL OF SMALL MOLECULE AGENTS TARGETING LYSINE DEACETYLASES: A MATTER OF SELECTIVITY?

— Boston, MA / Seng-Lai "Thomas" Tan, Ph.D. (Senior Director & Head of Immunology)

May 3, 2016 / Nature Reviews Drug Discovery

DRUG DEVELOPERS DELVE INTO THE CELL'S TRASH-DISPOSAL MACHINERY

March 10, 2016 / Watertown Tab & Press

WATERTOWN SCIENTIST READIES FOR 100-MILE ULTRAMARATHON